Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management

References

• OlsenEAKimYHKuzelTMPhase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphomaJ Clin Oncol200725213109311517577020
   PubMed Web of Science ®Google Scholar
• DuvicMTalpurRNiXPhase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood20071091313916960145
   PubMed Web of Science ®Google Scholar
• WhittakerSJDemierreMFKimEJFinal results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphomaJ Clin Oncol201028294485449120697094
   PubMed Web of Science ®Google Scholar
• PiekarzRLFryeRTurnerMPhase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaJ Clin Oncol200927325410541719826128
   PubMed Web of Science ®Google Scholar
• SchrumpDSFischetteMRNguyenDMClinical and molecular responses in lung cancer patients receiving romidepsinClin Cancer Res200814118819818172270
   PubMed Web of Science ®Google Scholar
• MolifeLRAttardGFongPCPhase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)Ann Oncol201021110911319608618
   PubMed Web of Science ®Google Scholar
• BaumanJVerschraegenCBelinskySA phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignanciesCancer Chemother Pharmacol201269254755421901396
   PubMed Web of Science ®Google Scholar
• EdenAGaudetFWaghmareAJaenischRChromosomal instability and tumors promoted by DNA hypomethylationScience2003300561845512702868
   PubMed Web of Science ®Google Scholar
• WangYLeungFCAn evaluation of new criteria for CpG islands in the human genome as gene markersBioinformatics20042071170117714764558
   PubMed Web of Science ®Google Scholar
• IrizarryRALadd-AcostaCWenBThe human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shoresNat Genet200941217818619151715
   PubMed Web of Science ®Google Scholar
• VaramballySCaoQManiRSGenomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancerScience200832259081695169919008416
   PubMed Web of Science ®Google Scholar
• GuentherMGLevineSSBoyerLAJaenischRYoungRAA chromatin landmark and transcription initiation at most promoters in human cellsCell20071301778817632057
   PubMed Web of Science ®Google Scholar
• BirdADNA methylation patterns and epigenetic memoryGenes Dev200216162111782440
   PubMed Web of Science ®Google Scholar
• EndresMFanGMeiselADirnaglUJaenischREffects of cerebral ischemia in mice lacking DNA methyltransferase 1 in post-mitotic neuronsNeuroreport200112173763376611726790
   PubMed Web of Science ®Google Scholar
• GaoQSteineEJBarrasaMIDeletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor progressionProc Natl Acad Sci U S A201110844180611806622011581
   PubMed Web of Science ®Google Scholar
• NoshoKShimaKIraharaNDNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancerClin Cancer Res200915113663367119470733
   PubMed Web of Science ®Google Scholar
• LinhartHGLinHYamadaYDnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencingGenes Dev200721233110312218056424
   PubMed Web of Science ®Google Scholar
• ListerRPelizzolaMDowenRHHuman DNA methylomes at base resolution show widespread epigenomic differencesNature2009462727131532219829295
   PubMed Web of Science ®Google Scholar
• ItoSShenLDaiQTet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosineScience201133360471300130321778364
   PubMed Web of Science ®Google Scholar
• Rodriguez-ParedesMEstellerMCancer epigenetics reaches mainstream oncologyNat Med201117333033921386836
   PubMed Web of Science ®Google Scholar
• CamposEIReinbergDHistones: annotating chromatinAnnu Rev Genet20094355959919886812
   PubMed Web of Science ®Google Scholar
• BeckDBBonasioRKanekoSChromatin in the nuclear landscapeCold Spring Harb Symp Quant Biol201175112221502408
   PubMedGoogle Scholar
• SawanCHercegZHistone modifications and cancerAdv Genet201070578520920745
   PubMed Web of Science ®Google Scholar
• BarskiACuddapahSCuiKHigh-resolution profiling of histone methylations in the human genomeCell2007129482383717512414
   PubMed Web of Science ®Google Scholar
• RosenfeldJAWangZSchonesDEZhaoKDeSalleRZhangMQDetermination of enriched histone modifications in non-genic portions of the human genomeBMC Genomics20091014319335899
   PubMed Web of Science ®Google Scholar
• LiBCareyMWorkmanJLThe role of chromatin during transcriptionCell2007128470771917320508
   PubMed Web of Science ®Google Scholar
• HuGCuiKNorthrupDH2A.Z facilitates access of active and repressive complexes to chromatin in embryonic stem cell self-renewal and differentiationCell Stem Cell201312218019223260488
   PubMed Web of Science ®Google Scholar
• HeintzmanNDHonGCHawkinsRDHistone modifications at human enhancers reflect global cell-type-specific gene expressionNature2009459724310811219295514
   PubMed Web of Science ®Google Scholar
• GaffneyDJMcVickerGPaiAAControls of nucleosome positioning in the human genomePLoS Genet2012811e100303623166509
   PubMed Web of Science ®Google Scholar
• BaylinSBJonesPAA decade of exploring the cancer epigenome – biological and translational implicationsNat Rev Cancer2011111072673421941284
   PubMed Web of Science ®Google Scholar
• WenBWuHLohYHBriemEDaleyGQFeinbergAPEuchromatin islands in large heterochromatin domains are enriched for CTCF binding and differentially DNA-methylated regionsBMC Genomics20121356623102236
   PubMed Web of Science ®Google Scholar
• KellerCAdaixoRStunnenbergRWoolcockKJHillerSBuhlerMHP1(Swi6) mediates the recognition and destruction of heterochromatic RNA transcriptsMol Cell201247221522722683269
   PubMed Web of Science ®Google Scholar
• FujimuraYIsonoKVidalMDistinct roles of Polycomb group gene products in transcriptionally repressed and active domains of Hoxb8Development2006133122371238116687444
   PubMed Web of Science ®Google Scholar
• AsanganiIAAteeqBCaoQCharacterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancerMol Cell2013491809323159737
   PubMed Web of Science ®Google Scholar
• BanerjeeRManiRSRussoNThe tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinomaOncogene201130424339434921532618
   PubMed Web of Science ®Google Scholar
• SakuraiTBilimVNUgolkovAVThe enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cellsBiochem Biophys Res Commun2012422460761422609199
   PubMed Web of Science ®Google Scholar
• EstellerMEpigenetics in cancerN Engl J Med2008358111148115918337604
   PubMed Web of Science ®Google Scholar
• FeinbergAPCancer epigenetics is no Mickey MouseCancer Cell20058426726816226700
   PubMed Web of Science ®Google Scholar
• FragaMFBallestarEVillar-GareaALoss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancerNat Genet200537439140015765097
   PubMed Web of Science ®Google Scholar
• SeligsonDBHorvathSShiTGlobal histone modification patterns predict risk of prostate cancer recurrenceNature200543570461262126615988529
   PubMed Web of Science ®Google Scholar
• YouJSJonesPACancer genetics and epigenetics: two sides of the same coin?Cancer Cell201222192022789535
   PubMed Web of Science ®Google Scholar
• DawsonMAKouzaridesTHuntlyBJTargeting epigenetic readers in cancerN Engl J Med2012367764765722894577
   PubMed Web of Science ®Google Scholar
• LeyTJDingLWalterMJDNMT3A mutations in acute myeloid leukemiaN Engl J Med2010363252424243321067377
   PubMed Web of Science ®Google Scholar
• JonesPABaylinSBThe epigenomics of cancerCell2007128468369217320506
   PubMed Web of Science ®Google Scholar
• IwamaAOguroHNegishiMEnhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1Immunity200421684385115589172
   PubMed Web of Science ®Google Scholar
• JacobsJJKieboomKMarinoSDePinhoRAvan LohuizenMThe oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locusNature199939767151641689923679
   PubMed Web of Science ®Google Scholar
• JonesPABaylinSBThe fundamental role of epigenetic events in cancerNat Rev Genet20023641542812042769
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular characterization of human colon and rectal cancerNature2012487740733033722810696
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkIntegrated genomic analyses of ovarian carcinomaNature2011474735360961521720365
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NComprehensive genomic characterization of squamous cell lung cancersNature2012489741751952522960745
   PubMed Web of Science ®Google Scholar
• FigueroaMEAbdel-WahabOLuCLeukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiationCancer Cell201018655356721130701
   PubMed Web of Science ®Google Scholar
• IssaJPCpG island methylator phenotype in cancerNat Rev Cancer200441298899315573120
   PubMed Web of Science ®Google Scholar
• TurcanSRohleDGoenkaAIDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeNature2012483739047948322343889
   PubMed Web of Science ®Google Scholar
• FangFTurcanSRimnerABreast cancer methylomes establish an epigenomic foundation for metastasisSci Transl Med201137575ra25
   PubMed Web of Science ®Google Scholar
• van den BentMJGravendeelLAGorliaTA hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951Clin Cancer Res201117227148715521914791
   PubMed Web of Science ®Google Scholar
• DelhommeauFDupontSDella ValleVMutation in TET2 in myeloid cancersN Engl J Med2009360222289230119474426
   PubMed Web of Science ®Google Scholar
• FerrariRPellegriniMHorwitzGAXieWBerkAJKurdistaniSKEpigenetic reprogramming by adenovirus e1aScience200832158921086108818719284
   PubMed Web of Science ®Google Scholar
• RastiMGrandRJMymrykJSGallimorePHTurnellASRecruitment of CBP/p300, TATA-binding protein, and S8 to distinct regions at the N terminus of adenovirus E1AJ Virol20057995594560515827174
   PubMed Web of Science ®Google Scholar
• CaoPDengZWanMMicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1betaMol Cancer2010910820478051
   PubMed Web of Science ®Google Scholar
• SmitsMNilssonJMirSEmiR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesisOncotarget20101871072021321380
   PubMedGoogle Scholar
• JeronimoCHenriqueRHoqueMOA quantitative promoter methylation profile of prostate cancerClin Cancer Res200410248472847815623627
   PubMed Web of Science ®Google Scholar
• BrooksJDWeinsteinMLinXCG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasiaCancer Epidemiol Biomarkers Prev1998765315369641498
   PubMed Web of Science ®Google Scholar
• HenriqueRJeronimoCMolecular detection of prostate cancer: a role for GSTP1 hypermethylationEur Urol2004465660669 discussion 66915474280
   PubMed Web of Science ®Google Scholar
• EstellerMGarcia-FoncillasJAndionEInactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agentsN Engl J Med2000343191350135411070098
   PubMed Web of Science ®Google Scholar
• PlumbJAStrathdeeGSluddenJKayeSBBrownRReversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoterCancer Res200060216039604411085525
   PubMed Web of Science ®Google Scholar
• BaylinSBOhmJEEpigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?Nat Rev Cancer20066210711616491070
   PubMed Web of Science ®Google Scholar
• Schneider-StockRDiab-AssefMRohrbeckA5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanismsJ Pharmacol Exp Ther2005312252553615547111
   PubMed Web of Science ®Google Scholar
• KellyTKDe CarvalhoDDJonesPAEpigenetic modifications as therapeutic targetsNat Biotechnol201028101069107820944599
   PubMed Web of Science ®Google Scholar
• KantarjianHIssaJPRosenfeldCSDecitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyCancer200610681794180316532500
   PubMed Web of Science ®Google Scholar
• SilvermanLRDemakosEPPetersonBLRandomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group BJ Clin Oncol200220102429244012011120
   PubMed Web of Science ®Google Scholar
• FenauxPMuftiGJHellstrom-LindbergEEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyLancet Oncol200910322323219230772
   PubMed Web of Science ®Google Scholar
• BlumWGarzonRKlisovicRBClinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineProc Natl Acad Sci U S A2010107167473747820368434
   PubMed Web of Science ®Google Scholar
• CashenAFSchillerGJO’DonnellMRDiPersioJFMulticenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemiaJ Clin Oncol201028455656120026803
   PubMed Web of Science ®Google Scholar
• YooCBJeongSEggerGDelivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotidesCancer Res200767136400640817616700
   PubMed Web of Science ®Google Scholar
• BruecknerBRiusMMarkelovaMRDelivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacyMol Cancer Ther2010951256126420442313
   PubMed Web of Science ®Google Scholar
• KuckDCaulfieldTLykoFMedina-FrancoJLNanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cellsMol Cancer Ther20109113015302320833755
   PubMed Web of Science ®Google Scholar
• SaundersLRVerdinESirtuins: critical regulators at the crossroads between cancer and agingOncogene200726375489550417694089
   PubMed Web of Science ®Google Scholar
• FedericoMBagellaLHistone deacetylase inhibitors in the treatment of hematological malignancies and solid tumorsJ Biomed Biotechnol2011201147564121188171
   PubMedGoogle Scholar
• LaneAAChabnerBAHistone deacetylase inhibitors in cancer therapyJ Clin Oncol200927325459546819826124
   PubMed Web of Science ®Google Scholar
• YounesASuredaABen-YehudaDPanobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II studyJ Clin Oncol201230182197220322547596
   PubMed Web of Science ®Google Scholar
• YounesAOkiYBociekRGMocetinostat for relapsed classical Hodgkin’s lymphoma: an open-label, single-arm, phase 2 trialLancet Oncol201112131222122822033282
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGAssoulineSCortesJPhase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemiaBlood2008112498198918495956
   PubMed Web of Science ®Google Scholar
• MackGSTo selectivity and beyondNat Biotechnol201028121259126621139608
   PubMed Web of Science ®Google Scholar
• YangZHeNZhouQBrd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progressionMol Cell Biol200828396797618039861
   PubMed Web of Science ®Google Scholar
• FilippakopoulosPQiJPicaudSSelective inhibition of BET bromodomainsNature201046873271067107320871596
   PubMed Web of Science ®Google Scholar
• NicodemeEJeffreyKLSchaeferUSuppression of inflammation by a synthetic histone mimicNature201046873271119112321068722
   PubMed Web of Science ®Google Scholar
• BalasubramanyamKVarierRAAltafMCurcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcriptionJ Biol Chem200427949511635117115383533
   PubMed Web of Science ®Google Scholar
• BalasubramanyamKAltafMVarierRAPolyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expressionJ Biol Chem200427932337163372615155757
   PubMed Web of Science ®Google Scholar
• SunYJiangXChenSPriceBDInhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiationFEBS Lett2006580184353435616844118
   PubMed Web of Science ®Google Scholar
• LallSPrimers on chromatinNat Struct Mol Biol200714111110111517984971
   PubMed Web of Science ®Google Scholar
• MetzgerEWissmannMYinNLSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcriptionNature2005437705743643916079795
   PubMed Web of Science ®Google Scholar
• LimSJanzerABeckerALysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biologyCarcinogenesis201031351252020042638
   PubMed Web of Science ®Google Scholar
• SchulteJHLimSSchrammALysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapyCancer Res20096952065207119223552
   PubMed Web of Science ®Google Scholar
• HuangYStewartTMWuYNovel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genesClin Cancer Res200915237217722819934284
   PubMed Web of Science ®Google Scholar
• WuYSteinbergsNMurray-StewartTMartonLJCaseroRAOligoamine analogues in combination with 2-difluoromethylornithine synergistically induce re-expression of aberrantly silenced tumour-suppressor genesBiochem J2012442369370122132744
   PubMed Web of Science ®Google Scholar
• WangJHeviSKurashJKThe lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylationNat Genet200941112512919098913
   PubMed Web of Science ®Google Scholar
• BrackenAPDietrichNPasiniDHansenKHHelinKGenome-wide mapping of Polycomb target genes unravels their roles in cell fate transitionsGenes Dev20062091123113616618801
   PubMed Web of Science ®Google Scholar
• AlbertMHelinKHistone methyltransferases in cancerSemin Cell Dev Biol201021220922019892027
   PubMed Web of Science ®Google Scholar
• GannonOEndo-MunozLBMerida de LongLHazar-RethinamMSaundersNADysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiationClin Cancer Res201319242844123186778
   PubMed Web of Science ®Google Scholar
• TanJYangXZhuangLPharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cellsGenes Dev20072191050106317437993
   PubMed Web of Science ®Google Scholar
• BradleyDRathkopfDDunnRVorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 ConsortiumCancer2009115235541554919711464
   PubMed Web of Science ®Google Scholar
• VansteenkisteJVan CutsemEDumezHEarly phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancerInvest New Drugs200826548348818425418
   PubMed Web of Science ®Google Scholar
• BlumenscheinGRJrKiesMSPapadimitrakopoulouVAPhase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancerInvest New Drugs2008261818717960324
   PubMed Web of Science ®Google Scholar
• RamalingamSSMaitlandMLFrankelPCarboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancerJ Clin Oncol2010281566219933908
   PubMed Web of Science ®Google Scholar
• StadlerWMMargolinKFerberSMcCullochWThompsonJAA phase II study of depsipeptide in refractory metastatic renal cell cancerClin Genitourin Cancer200651576016859580
   PubMed Web of Science ®Google Scholar
• GorgunGCalabreseEHideshimaTA novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myelomaBlood2010115255202521320382844
   PubMed Web of Science ®Google Scholar
• den HollanderJRimpiSDohertyJRAurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant stateBlood201011691498150520519624
   PubMed Web of Science ®Google Scholar
• MartinJAWangZNext-generation transcriptome assemblyNat Rev Genet2011121067168221897427
   PubMed Web of Science ®Google Scholar
• FureyTSChIP-seq and beyond: new and improved methodologies to detect and characterize protein-DNA interactionsNat Rev Genet2012131284085223090257
   PubMed Web of Science ®Google Scholar
• WongKMHudsonTJMcPhersonJDUnraveling the genetics of cancer: genome sequencing and beyondAnnu Rev Genomics Hum Genet20111240743021639794
   PubMed Web of Science ®Google Scholar
• HegiMEDiserensACGorliaTMGMT gene silencing and benefit from temozolomide in glioblastomaN Engl J Med200535210997100315758010
   PubMed Web of Science ®Google Scholar